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ABSTRACT 
 
Background: Primary Percutaneous Coronary Intervention Procedure (PPCI) results in 
reperfusion injury which will result in more extensive infarction. Remote Ischemic 
Postconditioning (RIPC) is a protective strategy to reduce the increase in the area of infarction. 
miRNA-145 also plays a role in the protective effect of IPC and RIPC. 
 
Research Methods: This study uses a pre and post test approach only with control group 
design with experimental research designs. Data is taken at the Integrated Heart Services 
Installation RSUP Dr. M. Djamil Padang from July to November 2019, 40 patients with ST-
segment elevation myocardial infarction (STEMI) performed RIPC. Bivariate analysis was 
performed to determine differences in levels of miRNA-145 and troponin I in STEMI patients 
underwent PPCI with and without RIPC using the Wilcoxon test and the Mann Whitney test. 
 
Results: A total of 40 patients who underwent the PPCI procedure were divided into two 
groups PPCI + RIPC (n = 20) and PPCI without RIPC (n = 20). There were no significant 
differences in the basic characteristics between the two groups. There were no significant 
difference in escalation of median expression of miRNA-145 in PPCI+ RIPC [pre test 36.33 
(27.44-52.39), post test 34.83 (27.65-65.26), p = 0.765] compared to PPCI without RIPC [pre 
test 31.66 (26.31-43.28), post test 33.43 (26.83-64.97), p = 0.765]. There were an increase in 
median troponin I levels in both groups, PPCI+ RIPC [pretest 4,104.70 (67.30-40,000.00), post 
test 30,448.50 (120.00-16.3192.20), p = 0.001] and PPCI without RIPC [pretest 826.50 (17.00-
48.259.00), post test 42.784.50 (2,119.00-162.897.00), p = <0.001].  
 
Conclusion: There were no significant difference in median expression of miRNA-145 in 
STEMI patients before and after (48 hours) underwent PPCI+RIPC and PPCI without RIPC. 
O
li
 Fi
rst
This article has been accepted for publication but has not been through the copyediting, typesetting, pagination and proofreading process.
doi: 10.30701/ijc.946
There were a significant difference in median levels of troponin I in STEMI patients before 
and after (48 hours) underwent PPCI+RIPC and PPCI without RIPC. 
Keywords: Remote Ischemic Postconditioning, miRNA-145, troponin I 
Introduction 
Acute myocardial infarction is one of the leading causes of death in the world and is 
associated with a poor prognosis.1 The incidence of STEMI in Europe ranges from about 43 to 
144 cases per 100,000 population per year. While in the United States reported incidents ranged 
from 50 cases per 100,000 population per year in 2008.2 In Indonesia in 2013 according to the 
Ministry of Health there were around 478,000 patients diagnosed with coronary heart disease 
with the prevalence of STEMI increasing from 20% to 40% of myocardial infarction.3 
Myocardial infarction occurs due to acute occlusion of the coronary arteries. The main markers 
of output of myocardial infarction patients are the size of myocardial infarction and left 
ventricular remodeling. The size of the infarction is related to cardiac troponin levels. Return 
of blood flow to an organ after a period of absence of flow results in parenchymal damage 
called ischemia reperfusion injury (IRI). The protective strategy for protecting organs from IRI 
is remote ischemic postconditioning (RIPC). Postconditioning is done by doing four ischemia 
limb cycles for 5 minutes (with tensimeter at the pump up to 200 mmHg) followed by 5 minutes 
of reperfusion in the first minute after the first balloon dilatation.4,5,6 
 miRNAs also play a role in the protective effects of IPC and RIPC through increased 
autophagy and axis of the Akt signal. miRNAs can be detected in peripheral circulation and 
can be found in a stable form. It is estimated that there are about 1000 miRNA in humans, one 
of which is miRNA-145 which is a mediator of the process of proliferation and differentiation 
of vascular smooth muscle cells (VSMCs) and is the most numerous miRNA in healthy artery 
walls. We chose miRNA-145 as a variable to evaluate because based on research Zhang et al 
(2017) found that decreased levels of miRNA-145 are associated with acute myocardial 
infarction and are a predictor of risk for heart failure, Yan et al (2018) stated that miRNA-145 
inhibits myocardial infarction induced by apoptosis via autophagy associated with the 
Akt3/mTOR pathway.1,7,8 
 The aim of this study was to evaluate the difference in miRNA-145 levels and 
troponin I levels in STEMI patients undergoing PPCI with RIPC and without RIPC. 
 
Methods 
 
 This research is an experimental study with a research design approach that is pre and 
post test only with control group design that is to measure the effect of treatment and compare 
between the experimental and control groups. This research was conducted at the Integrated 
Heart Services Installation RSUP Dr. M. Djamil Padang from July-November 2019. 
 Inclusion criteria, namely patients diagnosed with STEMI performed PPCI. 
Exclusion Criteria were PPCI failure (residual stenosis> 30% in culprit lesions), TIMI flow <3, 
GFR <30 ml / min / 1.73m2, hemodialysis, presence of other cardiac abnormalities 
(valvulopathy, cardiomyopathy, pericardial disease, congenital heart disease), consumption of 
glibenclamide (inhibits the effects of ischemic postconditioning), PAD, history of myocardial 
infarction, cardiomyopathy, pericardial disease, congenital heart disease), consumption of 
glibenclamide (inhibits the effects of ischemic postconditioning), PAD, history of myocardial 
infarction, cardiomyopathy, pericardial disease, congenital heart disease cardiogenic, pre and 
post cardiac arrest.  
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 With a paired analytical formula a large sample of 20 people for each group was 
obtained. Sampling was done by consecutive sampling. STEMI patients who came from the 
emergency room for the PPCI procedure were taken blood samples for examination of miRNA-
145 and troponin I. The RIPC procedure was performed shortly after cross wiring or cross 
balloon in the coronary arteries that had a blockage. The patient was given midazolam 1 mg 
and fentanyl 25 mcg intravenously as an analgesic. The patient is fitted with a 
sphygmomanometer cuff on the left upper arm and the cuff is inflated to 200 mmHg (and > 50 
mmHg above systolic blood pressure) for 5 minutes, deflate for 5 minutes for four cycles. 
Forty-eight hours after PPCI, the patient was taken a blood sample again for examination of 
troponin I and microRNA-145. Bivariate analysis was performed to determine differences in 
levels of miRNA-145 and troponin I in STEMI patients underwent PPCI with and without 
RIPC using the Wilcoxon test and the Mann Whitney test. 
 
Results 
 A total of 40 patients who underwent the PPCI procedure were divided into two 
groups PPCI + RIPC (n = 20) and PPCI without RIPC (n = 20). Table 4.1 and 4.2 showed the 
basic characteristic of the patients. There were no significant differences in the basic 
characteristics between the two groups.  
 
 
Table 4.1 Characteristics of Research Subjects 
 Variable  
 
p Value RIPC 
(n = 20) 
Without RIPC 
 (n = 20) 
Age (year), mean±SD 55,50±8,03 52,55±11,00 0,339a 
Sex (f/%) 
Male 
Female 
 
16 (80,0) 
4 (20,0) 
 
18 (90,0) 
2 (10,0) 
0,661 b 
Blood pressure, mean±SD 
Systolic 
Diastolic 
 
140,15±20,72 
82,00±13,92 
 
131,65±31,29 
82,40±20,31 
 
0,318 a 
0,943 a 
Body Mass Index (BMI), 
mean±SD 
23,56±2,85 25,18±3,49 0,117 a 
Hypertension (f/%) 12 (60,0) 8 (40,0) 0,343 b 
Diabetes mellitus (f/%) 4 (20,0) 3 (15,0) 1,000 b 
Smoker (f/%) 15 (75,0) 18 (90,0) 0,407 b 
Dyslipidemia (f/%) 7 (35,0) 6 (30,0) 1,000 b 
Family history (f/%) 1 (5,0) 0 n/a b 
Menopause (f/%) 4 (20,0) 2 (10,0) 0,661 b 
Heart rate (HR) , mean±SD 82,45±18,03 81,95±19,17 0,933 
*p<0,05 significant 
aindependent sample T test 
bchi-square 
 
Table 4.2 Characteristics of Research Subjects based on PPCI Results 
 Variable  
 
P Value RIPC 
(n = 20) 
Without RIPC 
 (n = 20) 
Ischemic Time (minutes) 370,85±198,76 300,40±144,19 0,207 a 
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STEMI 
STEMI Anterior 
 
12 (60,0) 
 
6 (30,0) 
n/a b 
STEMI Anterior Ekstensif 3 (15,0) 5 (25,0)  
STEMI Inferior 4 (20,0) 3 (15,0)  
STEMI Inferoposterior 1 (5,0) 3 (15,0)  
STEMI Inferior + RV 0 3 (15,0)  
Vessel Disease (VD) 
1 VD 
2 VD 
3 VD 
 
5 (25,0) 
5 (25,0) 
10 (50,0) 
 
9 (45,0) 
7 (35,0) 
4 (20,0) 
0,132 b 
Infarct Related Artery (IRA) (%) 
LAD 
LCX 
RCA 
 
15 (75,0) 
0 
5 (25,0) 
 
12 (60,0) 
1 (5,0) 
7 (35,0) 
n/a b 
  
Killip 
I 
II 
 
19 (95,0) 
1 (5,0) 
 
18 (90,0) 
2 (10,0) 
1,000 b 
*p<0,05 significant 
aindependent sample T test 
bchi-square 
 
Table 4.3 Differences in miRNA-145 Expression in STEMI Patients Underwent PPCI with 
RIPC and without RIPC 
 
 
Variable 
PPCI 
RIPC p 
value 
Without RIPC p 
value Pretest 
Median 
(Min-Maks) 
Posttest 
(48 hours) 
Median 
(Min-Maks) 
Pretest 
Median 
(Min-Maks) 
Posttest 
(48 hours) 
Median 
(Min-Maks) 
miRNA145 36,33  
(27,44-52,39) 
34,83  
(27,65-65,26) 
0,765 31,66  
(26,31-43,28) 
33,43  
(26,83-64,97) 
0,765 
 
 
Table 4.4 Difference in ∆ miRNA-145 Expression in STEMI Patients Underwent PPCI with 
RIPC and without RIPC 
 
Variable 
PPCI  
p value RIPC 
Median (Min-Maks) 
Without RIPC 
Median (Min-Maks) 
∆ miRNA145 - 0,46 
(-24,74-29,11) 
0,02 
(-9,32-33,40) 
1,000 
 
 There were no significant difference in escalation of median expression of miRNA-
145 in PPCI+ RIPC [pre test 36.33 (27.44-52.39), post test 34.83 (27.65-65.26), p = 0.765] 
compared to PPCI without RIPC [pre test 31.66 (26.31-43.28), post test 33.43 (26.83-64.97), 
p = 0.765]. miRNA-145 expression is assessed from Cq, where Cq is defined as the number of 
PCR cycles when fluorescence meets the threshold of the amplification plot. The smaller the 
number that appears indicates the fewer PCR cycles needed to reach the threshold, which 
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means more miRNA-145 expressions. Although not statistically significant, ∆ miRNA-145 in 
subjects conducted by PPCI+RIPC is more negative which means that miRNA-145 expression 
has increased [PPCI + RIPC group [- 0.46 (-24.74-29.11), PPCI without RIPC group [0.02 (-
9.32-33.40), p = 1,000].  
 
Table 4.5 Differences in Troponin I Levels in STEMI Patients Underwent PPCI with RIPC and 
without RIPC 
 
 
Variable 
PPCI 
RIPC p 
value 
Without RIPC p value 
Pretest 
Median 
(Min-Maks) 
Posttest 
(48 hours) 
Median 
(Min-Maks) 
Pretest 
Median 
(Min-
Maks) 
Posttest 
(48 hours) 
Median 
(Min-Maks) 
Troponin I 4.104,70 
(67,30-
40.000,00) 
30.448,50 
(120,00-
16.3192,20) 
0,001* 826,50 
(17,00-
48.259,00 
42.784,50 
(2.119,00-
162.897,00) 
<0,001* 
 
 
 
Table 4.6. Differences in ∆ Troponin I Levels in STEMI Patients Underwent PPCI with RIPC 
and without RIPC 
 
 
Variable 
PPCI  
p value RIPC 
Median (Min-Maks) 
Without RIPC 
Median (Min-Maks) 
∆ Troponin I 19.736,00 
(-12.235,0-123.364,20) 
41.478,35 (1.792,00-
163.638,00) 
0,007* 
 
 There was an increase in median troponin I levels in both groups, PPCI+ RIPC 
[pretest 4,104.70 (67.30-40,000.00), post test 30,448.50 (120.00-16.3192.20), p = 0.001] and 
PPCI without RIPC [pretest 826.50 (17.00-48.259.00), post test 42.784.50 (2,119.00-
162.897.00), p = <0.001]. There is significant difference in median ∆ Troponin I in the PPCI 
+ RIPC group [19,736.00 (-12,235.0-123,364.20)] compared to the PPCI without RIPC group 
[41,478.35 (1,792.00-163,638.00)], p = 0.007. 
 
Discussion 
 In this study, the median expression of miRNA-145 in subjects before and 48 hours 
after the PPCI action with RIPC showed p values that were not statistically significant (p = 
0.765). Median miRNA-145 expression in subjects before and 48 hours after the PPCI action 
without RIPC was also obtained p-values that were not statistically significant (p = 0.765). 
Although statistically it does not have a significant difference value, it can be seen that the 
expression of miRNA145 in subjects made by PPCI with RIPC has increased compared to 
subjects not done by RIPC. This result is in line with Liu et al who found that overexpression 
of miRNA-145 had a protective effect against reperfusion injury in rat myocardium.9 
 Higashi et al conducted a study on rabbits that were made to have coronary occlusion 
and injected miRNA-145. The results found that the group receiving miRNA-145 had a smaller 
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infarction area and increased left ventricular function. This cardioprotective effect arises from 
an increase in autofagi and activation of the Akt signal axis, where this effect appears within 
two days after myocardial infarction and lasts for up to two weeks thereafter.14 This is 
consistent with those conducted by researchers where miRNA-145 expression and infarct area 
were assessed from Troponin I levels are seen before reperfusion and 48 hours after.10 Wei et 
al stated that patients with coronary artery disease had lower expression of miRNA-126, 
miRNA-145 and miRNA-155.11 According to Rangrez et al there was a significant decrease in 
expression of miRNA-145 to almost undetectable in atherosclerotic lesions. Fichtlscherer et al. 
stated a significant decrease in miRNA-145 in the blood of patients with coronary artery 
disease compared with healthy individuals. miRNA itself is a master gene regulators that can 
target multiple genes, so miRNA can affect various cellular pathways. Therefore, the selection 
of therapeutic targets based on miRNA must consider the possibility that one miRNA can play 
a role in more than one physiological process.12,13,14 
 In this study, the median level of troponin I obtained in subjects before the PPCI with 
RIPC was 4,104.70 (67.30-40,000.00) higher than subjects before the PPCI  without RIPC was 
826.50 (17.00-48.259, 00). This could be due to the greater number of subjects in the RIPC 
group who experienced anterior STEMI with infarct related artery in LAD which caused a 
relatively greater infarction area marked by higher troponin I levels. Table 4.5 known troponin 
I levels in subjects after RIPC action was 30,448.50. Based on the results of statistical tests 
using the Wilcoxon test obtained p value = 0.001 (p <0.05), meaning that there are significant 
differences in troponin I levels in STEMI patients who underwent PPCI with RIPC before and 
after treatment. The median level of troponin I in the PPCI group that was not performed by 
the RIPC 48 hours after was 42,784.50. Based on the results of statistical tests using the 
Wilcoxon test obtained p = <0.001 (p <0.05), meaning that there are significant differences in 
troponin I levels in STEMI patients undergoing PPCI without RIPC before and after treatment. 
However, if seen from groups conducted by PPCI with RIPC, they experienced an increase in 
troponin I levels which were lower than those conducted by PPCI alone. 
 This is in line with research conducted by Bangming Cao et al who assessed CKMB 
levels at 0.5, 8, 24, 48 and 72 hours after PPCI in groups undergoing PPCI + RIPC and PPCI 
only. A significant difference was found in the lower CKMB concentration in the PPCI + RIPC 
group and compared to the PPCI group alone and it was concluded that the infarct area was 
smaller in the PPCI + RIPC group than the PPCI group alone (p = 0.02) .7 Thuny et al 
conducted a study of 50 STEMI patients who underwent PPCI and received RIPC were 
statistically significant in reducing the area of infarction, levels of creatine kinase and 
myocardial edema.7,15 
 Thibault et al. Found an average 47% reduction in the troponin I under curve area in 
the postconditioning group compared with the control group and after one year the 
postconditioning group showed an increase in the left ventricular ejection fraction by 7% 
compared to the control group. Research conducted by White et al in 2015 of 197 STEMI 
patients with TIMI Flow 0 who randomly received RIPostC 4x5 minutes of inflation / deflation 
in the upper limb for a moment when PPCI produced a 27% reduction in infarction area 
measured by CMR as well as an increase in myocardial salvage index and decreased 
myocardial edema. Lonborg et al. assessed the effect of postconditioning on 118 patients 
divided by 1: 1 undergoing PPCI + postconditioning or PPCI alone. Assessed troponin I and 
cardiac MRI (CMR) peaks and a significant reduction in infarction in the postconditioning 
group, ST segment elevation resolution, reduction in infarction size by 19% in three months 
and reduction in heart failure (27% vs 46%; p = 0.048). Remote protocol selection in upper or 
lower limb organs in a randomized study showed no significant difference in the results 
obtained. Research conducted by Zhu et al in 2013 shows that the preconditioning and 
postconditioning strategies have similar therapeutic potential for cardiac ischemia / reperfusion 
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injury. However, the selection of RIPostC procedures rather than RIPreC is done because there 
is often a lack of time for RIPreC procedures.16,17,18,19 
 The CONDI-2 / ERIC-PPCI randomized controlled trial in 2019 conducted at 33 
centers in the UK, Denmark, Spain and Serbia stated that remote ischemic conditioning does 
not improve clinical outcomes (cardiac death or hospitalization for heart failure) at 12 months 
in patients with STEMI undergoing PPCI.20 In CONDI-2/ERIC-PPCI the remote ischemic 
conditioning procedure was performed before PPCI (RIPreC), while in this study the procedure 
was carried out shortly after crosswiring (RIPostC). The reason in this study using RIPostC 
procedure is that the remote ischemic conditioning procedure does not delay the time of PPCI 
to be performed on patients. This study assessed two variables namely miRNA-145 and 
troponin I initial and 48 hours after the treatment, while in CONDI-2/ERIC-PPCI clinical 
outcomes evaluation was conducted 12 months after PPCI. For this reason, this study requires 
a long-term evaluation to confirm the clinical outcomes of research subjects. 
 
Research Limitations 
 The absence of standard miRNA-145 expression in STEMI patients and the function 
of miRNA as master gene regulators that can target multiple genes is also a limitation of this 
study, so it is necessary to examine several miRNAs that play a role in myocardial infarction. 
The location of the anterior STEMI is a confounding variable in this study, so uniformity of 
the STEMI location is required for future studies. This study took STEMI patients, both total 
and non total-occlusion. The results of this study should be confirmed by imaging examination 
with CMR to confirm the calculation of infarct area. It is also necessary to examine other 
cardioprotective mediators that play a role in RIPC such as Stromal Derived Factor-1α, 
Adenosine, Nitrite, Interleukin-10, and Interleukin-1 α. 
 
Conclusion 
There was an increase in miRNA-145 expression in PPCI+RIPC group compare to PPCI 
without RIPC group, but not statistically significant. There was a significant difference in the 
reduction in infarct area from median levels of troponin I in STEMI patients before and after 
(48 hours) underwent PPCI+RIPC and PPCI without RIPC. Patients underwent PPCI+RIPC 
had lower increase of troponin I compare to patients underwent PPCI without RIPC group.  
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